11 active not recruiting, 3 recruiting, 2 completed. 7 Phase 1, 7 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Ovarian High Grade Serous Adenocarcinoma: new trials by email Literature Review of Ovarian High Grade Serous Adenocarcinoma trials Research Report on Ovarian High Grade Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Uterine Lavage to Detect Ovarian Cancer Risk Uterine Lavage, Archive Sample, Survey Administration - BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Not applicable | Recruiting | University of Washington | 75 | 2026-09-03 | 2026-09-14 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer Atovaquone, Biopsy, Computed Tomography - Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Recruiting | Emory University | 28 | 2023-11-09 | 2026-10-01 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Biopsy Procedure, Carboplatin, Ipatasertib - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2022-09-08 | 2026-09-22 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| National Cancer Institute "Cancer Moonshot Biobank" Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8 | Active not recruiting | National Cancer Institute (NCI) | 1600 | 2020-11-11 | 2026-10-05 | |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 61 | 2019-12-04 | 2026-08-26 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Anetumab Ravtansine, Bevacizumab, Paclitaxel - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2018-10-12 | 2026-10-13 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-22 |
| Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Berzosertib, Carboplatin, Gemcitabine Hydrochloride - Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-05-16 | 2026-07-31 |
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Paclitaxel, Ruxolitinib Phosphate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Completed | NRG Oncology | 147 | 2016-11-14 | 2025-05-25 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-05-23 | 2026-09-29 |
| Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2016-02-04 | 2026-10-06 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 155 | 2010-04-14 | 2026-07-14 |
Fallopian Tube Neoplasms (11) · Ovarian Neoplasms (8) · Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Adnexal Diseases (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genital Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Neoplasms by Site (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Fallopian Tube Diseases (11) · Neoplasms (10) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Gonadal Disorders (8) · Ovarian Diseases (8)
Specimen Handling (7) · Magnetic Resonance Spectroscopy (6) · Biopsy (5) · Bevacizumab (4) · Disulfides (4) · Immunoglobulin G (4) · Taxes (4) · olaparib (4) · Carboplatin (3) · Paclitaxel (3) · Doxorubicin (2) · Gemcitabine (2) · Paracentesis (2) · cediranib (2) · liposomal doxorubicin (2)
National Cancer Institute (NCI) (10) · NRG Oncology (2) · Emory University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · University of Washington (1)
United States (16) · Puerto Rico (3) · Canada (1) · Japan (1)
Joyce F Liu (2) · Andrea E Wahner Hendrickson (1) · Barbara Norquist, MD (1) · Charles N Landen (1) · James M Cleary (1) · Katherine C Fuh (1) · Lyndsay N Harris (1) · Matthew S. Block, M.D., Ph.D. (1) · Namita Khanna, MD, MSPH (1) · Rachel N Grisham (1) · Roisin E O'Cearbhaill (1) · Sarah F Adams (1) · Shannon N Westin (1) · Stephanie Lheureux (1) · Ying Liu (1)
PMID 37185961, PMID 23810467, PMID 25218906, PMID 32379297, PMID 38776484
U10CA180868 (5), UM1CA186709 (4), UM1CA186644 (2), UM1CA186686 (2), UM1CA186691 (2), N01CM00071 (1), N01CM00099 (1), P30CA006516 (1), P30CA015083 (1), P30CA138292 (1), U01CA062490 (1), UM1CA186690 (1), UM1CA186704 (1), UM1CA186712 (1), UM1CA186716 (1)